Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery (IPOD-3)
Primary Purpose
Gastrointestinal Cancer
Status
Terminated
Phase
Phase 3
Locations
Switzerland
Study Type
Interventional
Intervention
Immunonutrition
Sponsored by
About this trial
This is an interventional treatment trial for Gastrointestinal Cancer focused on measuring Immunonutrition, cancer, GI cancer surgery
Eligibility Criteria
Inclusion Criteria:
- Patients with GI cancer (stomach, pancreas, small and large bowel and rectum) histologically proven
- Well nourished patients as defined by a total score of <3 on the nutritional screening tool NRS-2002 (46) (Appendix III)
- Patients who are >= 18 years of age;
- Patients who have signed a written Informed Consent (Appendix I) prior to admission to the study;
- Patients who have an ECOG performance status of 0, 1 or 2 (Appendix II).
- Patients able to orally consume 750 mL or more of liquid a day prior to surgery
Exclusion Criteria:
- Patients who have co-morbid conditions, uncontrolled metabolic conditions or psychiatric conditions that might make tolerance or evaluation of the feeding formula difficult;
- Patients who are pregnant;
- Patients with cardiac failure as defined by the Goldman classification class>3
- Patients with respiratory failure (FEV<0.8l/sec)
- Patients with renal failure (Cr >= 3mg/dl or dialysis patients)
- Patients with hepatic dysfunction (Child >A)
- Patients suffering from an intestinal obstruction or ileum
- Patients with an Hb level of <=8 g/dL experiencing gastrointestinal hemorrhaging
- Patients with HIV, HCV, HBV
- Patients requiring immunosuppression treatments
- Patients undergoing emergency surgery
- Other patients determined by a study investigator to be inappropriate for enrolment in this study
Sites / Locations
- Kantonsspital Aarau
- Kantonsspital Baden
- Lindenhof-Spital
- Kantonsspital Liestal
- Kantonsspital Schaffausen
- Kantonsspital St.Gallen
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Nutritional product
Isocaloric control
Arm Description
Oral nutritional supplement containing immuno nutrients
Isocaloric and isonitrogenous control without immuno nutrients
Outcomes
Primary Outcome Measures
Rate of post-operative complications
Secondary Outcome Measures
Incidence of non-infectious complications
Length of hospital stay
Nutritional status evaluation
Rate of post-operative infectious complications
Full Information
NCT ID
NCT01023412
First Posted
November 16, 2009
Last Updated
April 24, 2012
Sponsor
Société des Produits Nestlé (SPN)
1. Study Identification
Unique Protocol Identification Number
NCT01023412
Brief Title
Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery
Acronym
IPOD-3
Official Title
Effect of 3 Day Pre-operative Immunonutrition Regimen on Clinical Outcome in Well-nourished Patients With Gastrointestinal Cancer Undergoing Surgery , a Randomised Double-blind Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2012
Overall Recruitment Status
Terminated
Why Stopped
interim review of the data indicated that the hypothesis put forth on the efficacy of a 3 day regimen was not met.
Study Start Date
January 2006 (undefined)
Primary Completion Date
May 2008 (Actual)
Study Completion Date
May 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Société des Produits Nestlé (SPN)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Major surgery is still associated with a high rate of postoperative morbidity despite improved techniques in surgical management. Surgery-induced alterations of the immune system are well described and may play a role in the genesis of postoperative complications. It has been shown by several large scale clinical trials, that the use of immunonutrition in postoperative cancer surgery, trauma and critically ill patients resulted in an improved immunocompetence and/or reduced postoperatively infectious morbidity and/or length of hospital stay.The pre-operative regimen was between 5 to 7 days of treatment. The aim of this trial is to evaluate if a shorter administration of 3 days pre-operatively would be beneficial as well.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Cancer
Keywords
Immunonutrition, cancer, GI cancer surgery
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
107 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nutritional product
Arm Type
Active Comparator
Arm Description
Oral nutritional supplement containing immuno nutrients
Arm Title
Isocaloric control
Arm Type
Placebo Comparator
Arm Description
Isocaloric and isonitrogenous control without immuno nutrients
Intervention Type
Dietary Supplement
Intervention Name(s)
Immunonutrition
Intervention Description
Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
Primary Outcome Measure Information:
Title
Rate of post-operative complications
Time Frame
On the day of discharge from hospital
Secondary Outcome Measure Information:
Title
Incidence of non-infectious complications
Time Frame
On the day of discharge from hospital
Title
Length of hospital stay
Time Frame
On the day of discharge from hospital
Title
Nutritional status evaluation
Time Frame
On the day of discharge from hospital
Title
Rate of post-operative infectious complications
Time Frame
On the day of discharge from hospital
10. Eligibility
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with GI cancer (stomach, pancreas, small and large bowel and rectum) histologically proven
Well nourished patients as defined by a total score of <3 on the nutritional screening tool NRS-2002 (46) (Appendix III)
Patients who are >= 18 years of age;
Patients who have signed a written Informed Consent (Appendix I) prior to admission to the study;
Patients who have an ECOG performance status of 0, 1 or 2 (Appendix II).
Patients able to orally consume 750 mL or more of liquid a day prior to surgery
Exclusion Criteria:
Patients who have co-morbid conditions, uncontrolled metabolic conditions or psychiatric conditions that might make tolerance or evaluation of the feeding formula difficult;
Patients who are pregnant;
Patients with cardiac failure as defined by the Goldman classification class>3
Patients with respiratory failure (FEV<0.8l/sec)
Patients with renal failure (Cr >= 3mg/dl or dialysis patients)
Patients with hepatic dysfunction (Child >A)
Patients suffering from an intestinal obstruction or ileum
Patients with an Hb level of <=8 g/dL experiencing gastrointestinal hemorrhaging
Patients with HIV, HCV, HBV
Patients requiring immunosuppression treatments
Patients undergoing emergency surgery
Other patients determined by a study investigator to be inappropriate for enrolment in this study
Facility Information:
Facility Name
Kantonsspital Aarau
City
Aarau
ZIP/Postal Code
5001
Country
Switzerland
Facility Name
Kantonsspital Baden
City
Baden
ZIP/Postal Code
5404
Country
Switzerland
Facility Name
Lindenhof-Spital
City
Bern
ZIP/Postal Code
3012
Country
Switzerland
Facility Name
Kantonsspital Liestal
City
Liestal
ZIP/Postal Code
4410
Country
Switzerland
Facility Name
Kantonsspital Schaffausen
City
Schaffhausen
ZIP/Postal Code
8208
Country
Switzerland
Facility Name
Kantonsspital St.Gallen
City
St.Gallen
ZIP/Postal Code
9000
Country
Switzerland
12. IPD Sharing Statement
Learn more about this trial
Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery
We'll reach out to this number within 24 hrs